PRESENTATION

Q4 2023 — Presentation

Q4 2023PDF · 32 pages2.3 MB
Merck
Q4 2023 Earnings
February 1, 2024

-- 1 of 32 --

Agenda
2
Strategy and
Business Update
Rob Davis
Chairman and Chief
Executive Officer
Question & Answer
Session
Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer
Research
Update
Dr. Dean Li
President, Merck
Research Laboratories

-- 2 of 32 --

Forward-looking statement of Merck & Co., Inc.,
Rahway, N.J., USA
3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of
the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and
are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary
regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency
exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health
care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future
market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the
company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report
on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).

-- 3 of 32 --

Strategy and
Business Update
Rob Davis
Chairman and Chief Executive Officer

-- 4 of 32 --

Committed to saving and improving lives around the world
5
More than 500
million people
reached with
our medicines
in 2023

-- 5 of 32 --

Delivered on our key strategic priorities in 2023
Advanced the pipeline to meet
patient unmet need
Achieved strong commercial and
financial performance
Executed on strategic business
development to augment pipeline
Created long-term value for patients
and shareholders
6

-- 6 of 32 --

0
10,000
20,000
30,000
40,000
50,000
60,000
70,000
2021 	2022 	2023 	2024
Strong 2023 underlying performance1 and 2024 initial guidance
7
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Excludes LAGEVRIO sales of $193 million in 4Q23 and $825 million in 4Q22. 3. Merck does not exclude expenses for
upfront and milestone payments related to certain collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions
from its non-GAAP results. Full year non-GAAP results for 2023, 2022 and 2021 include $6.21, $0.22 and $0.65 per share of such charges, respectively. 4. GAAP Loss per Share ($0.48).
$14.6B
+6%
+13% ex-Exchange, ex-LAGEVRIO 2
Q4 Worldwide Sales
$0.03
Includes one-time charge of $1.69
per share from the collaboration
with Daiichi Sankyo
Q4 Non-GAAP EPS4
$48.7B
+17%
$5.37
Full Year Sales
Full Year Non-GAAP EPS3
$59.3B
+22%
$60.1B
+1%
2021 	2022 	2023 	2024
$1.51
$5.37
$7.48
GUIDANCE RANGE
$62.7B - $64.2B
+4% - +7%
GUIDANCE RANGE
$8.44 - $8.59

-- 7 of 32 --

8
Maximizing potential impact for patients with our expansive pipeline
Vaccines	Cardiometabolic 	Oncology
Sotatercept
Seeking to transform
treatment paradigm for
patients with pulmonary
arterial hypertension
V116
Pursuing approval for
the first pneumococcal
conjugate vaccine
specifically designed
for adults
Diverse Portfolio
& Pipeline
Broadening reach to more
patients with potential to
improve outcomes

-- 8 of 32 --

Expanding robust pipeline with opportunity for patient impact
and value creation well into the next decade
9
Oncology
(excludes innovation from marketed products)
Cardiometabolic
Immunology
Prior Outlook 	Current Outlook
>$10B
Includes TROP-21 , ROR-1, CYP11A1i2, LSD-1i,
KRASi, BTKi and others
>$20B
Now includes HER3, B7H3 and CDH6 ADCs3
and V940 (INT) 4
~$15B
Now includes MK-6024, and reflects increased
confidence supported by clinical data readouts for
sotatercept and MK-0616
>$10B
Includes sotatercept, MK-0616, MK-2060,
MK-5475 and Verquvo5
Multibillion
in each indication (CD and UC) for tulisokibart
Multibillion
in each indication (CD and UC) for tulisokibart
Additional Opportunities in Late-Phase Pipeline Programs Across Vaccines, Neurosciences,
HIV and Animal Health, Early-Phase Programs & Additional Potential Business Development
Note: All dollar figures above are non-risk adjusted annual sales by the mid 2030s
1. Collaboration with Kelun Biotech 2. Collaboration with Orion 3. Collaboration with Daiichi Sankyo 4. Collaboration with Moderna
5. Collaboration with Bayer, includes expanded indication to chronic heart failure without a worsening event for Verquvo

-- 9 of 32 --

Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer

-- 10 of 32 --

Strong underlying Q4 and 2023 worldwide sales growth
11
4Q 2023 WORLDWIDE SALES1
$14.6B+6% growth
+11% ex-LAGEVRIO3
+13% ex-exchange, ex-LAGEVRIO 3
$13.1B
+8% growth
+14% ex-LAGEVRIO 3
+14% ex-exchange, ex-LAGEVRIO 3
Human Health
$1.3B
+4% growth
+4% ex-exchange
Animal Health
1. Worldwide Sales includes Other Revenue. 2. Excludes LAGEVRIO sales of $1.4 billion in 2023 and $5.7 billion in 2022.
3. Excludes LAGEVRIO sales of $193 million in 4Q23 and $825 million in 4Q22.
FULL YEAR WORLDWIDE SALES1
$60.1B+1% growth
+9% ex-LAGEVRIO2
+12% ex-exchange, LAGEVRIO2
Merck

-- 11 of 32 --

Oncology: KEYTRUDA continues to benefit patients globally
12	Growth rates exclude the impact of foreign exchange.
• KEYTRUDA sales of $6.6B increased 22%
driven by global uptake in earlier stage
cancers, including TNBC and RCC, and
strong global demand from metastatic
indications
• Encouraging signs in treating certain
patients with earlier stage NSCLC based on
recent approvals
• Positive initial feedback from healthcare
providers following recent launch in
advanced urothelial cancer
$4.2B
+20%
$3.4B
+31%
$5.3B
+30%
4Q21 	4Q22 	4Q23
$5.5B
+26%
$4.6B
+16%
$6.6B
+22%

-- 12 of 32 --

Oncology: Solid performance across broad portfolio
• Lynparza 1 sales grew 8% driven primarily by
pricing in the U.S. and higher demand in
international markets
• Lenvima 2 sales grew 5% driven by higher
demand in the U.S., partially offset by
shipment timing in China
• WELIREG sales increased 78% driven by
increased uptake in VHL-associated tumors
– Opportunity to treat certain patients with
previously treated advanced RCC based on
LITESPARK-005 $181M
+15%
$151M
+57%
13	Growth rates exclude the impact of foreign exchange.
1. In collaboration with AstraZeneca 2. In collaboration with Eisai
4Q21 	4Q22 	4Q23
$292M
+14%
$268M
+33%
$315M
+8%
4Q21 	4Q22 	4Q23
$216M
+9%
$206M
+31%
$226M
+5%
4Q21 	4Q22 	4Q23
$40M
+245%
$12M
$72M
+78%

-- 13 of 32 --

Vaccines: Robust growth driven by GARDASIL
14
• GARDASIL sales of $1.9B increased 27%
year-over-year driven by strong global
demand, particularly in China
– In the U.S., sales benefited from CDC
purchasing patterns
• VAXNEUVANCE growth driven by
launches in Europe and continued uptake
of pediatric indication in the U.S.
– 4Q 2022 benefited from inventory stocking
in the U.S. ahead of pediatric launch
$1.2B
+78%
$656M
-24%
$1.7B
+40%
4Q21 	4Q22 	4Q23
$1.5B
+6%
$1.5B
+50%
$1.9B
+27%
Growth rates exclude the impact of foreign exchange.

-- 14 of 32 --

Hospital: Continued patient impact across portfolio
15
• BRIDION sales declined 3% as increased
market share among neuromuscular
blockade reversal agents in the U.S. was
more than offset by the impact of
generic entrants in international
markets, particularly in Europe
• PREVYMIS sales grew 49% driven by
continued strong global demand
$387M
+67%
$224M
-18%
$426M
+15%
4Q21 	4Q22 	4Q23
$441M
+7%
$436M
+24%
$429M
-3%
$93M
+41%$63M
+67%
$103M
+18%
$94M
+20%
$82M
+31%
$129M
+44%
Increase/decrease excludes the impact of foreign exchange.
4Q21 	4Q22 	4Q23
$118M
+28%$100M
+27%
$175M
+49%

-- 15 of 32 --

Animal Health: Solid growth driven by companion animal
16
• Animal Health sales increased 4% to $1.3B
– Companion Animal sales increased 12% driven
by BRAVECTO line of products due to strong
underlying demand and shipment timing
– Livestock sales were flat reflecting favorable
price actions offset by timing of ruminant
product shipments $1.5B
+27%
$1.1B
+3%
$1.5B
+5%
4Q21 	4Q22 	4Q23
$1.2B
+6%
$1.3B
+8%
$1.3B
+4%
Growth rates exclude the impact of foreign exchange.

-- 16 of 32 --

Q4 2023 non-GAAP financial results summary1
Q4 2023 	Q4 2022 	Change Change
Ex-FX
Sales 	$14.6 	$13.8 	+6% 	+7%
Non-GAAP Gross Margin 	77.2% 	75.7% 	+1.5pts 	+2.5pts
Non-GAAP Operating
Expenses $11.6 	$5.7 	>100% 	>100%
Non-GAAP Tax Rate 	114.2% 	15.6% 	>100% 	N/A
Non-GAAP EPS2,3 $0.03 	$1.62 	-98% 	>100%
$ in billions, except EPS amounts
17
1. Merck is providing certain 2023 and 2022 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business
performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to,
information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q4 2023 includes $5.5 billion charge, or $1.69
negative EPS impact, for the collaboration with Daiichi Sankyo. 3. Q4 2023 GAAP Loss per Share of ($0.48).

-- 17 of 32 --

Initial 2024 financial outlook implies strong growth
1. Guidance does not assume any additional significant potential business development transactions.
2. One royalty on KEYTRUDA stepped down from 6.5% to 2.5% on 1/1/2024; One royalty on GARDASIL expired on 1/1/2024.
18
Guidance 	Key Assumptions
Revenue 	$62.7B to $64.2B • 	Implies growth of +4% to +7% (+6% to +9% ex-FX)
• 	Assumes ~2 ppt FX headwind
Non-GAAP
Gross Margin Rate ~80.5% • 	Includes the benefit from reduced royalties paid on KEYTRUDA and
GARDASIL2
Non-GAAP
Operating Expenses1 	$25.1B to $26.1B • 	Includes ~$650M one-time charge related to the announced
acquisition of Harpoon Therapeutics
Other (Income) / Expense 	~$200M of expense
Tax Rate 	~14.5% to 15.5%
Shares Outstanding 	~2.54B
Non-GAAP EPS 	$8.44 to $8.59 • 	Includes one-time ~$0.26 charge related to Harpoon Therapeutics
• 	Includes a negative impact from FX of ~$0.25

-- 18 of 32 --

19
Augmenting our pipeline
with value enhancing
business development while
continuing to invest in our
pipeline and business
$2.8
$1.0
$1.9
$5.6
$0.4
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
Q4 Spend ($ in billions):
1. Reflects R&D excluding Business Development
Remain committed to balanced capital allocation strategy
Capital allocation order of priority
1

-- 19 of 32 --

Research Update
Dr. Dean Li
President, Merck Research Laboratories

-- 20 of 32 --

Diversifying our oncology program and executing on our strategy
Precision Molecular Targeting
Impact pathways that can drive
cancer growth
Tissue Targeting
Increase cancer cell sensitivity
with ADCs and immune-engagers
Immuno-oncology
Boost anti-tumor immune
responses
quavonlimab/pembro
(MK-1308A)
anti-CTLA-4
vibostolimab/pembro
(MK-7684A)
anti-TIGIT
MK-4830
anti-ILT-4
zilovertamab vedotin
(MK-2140)
ROR1 ADC
nemtabrutinib
(MK-1026)
BTK inhibitor
MK-56844
CYP11A1 inhibitor
V9401
Individualized
Neoantigen Therapy
MK-1484
IL-2 Rβɣ
bomedemstat
(MK-3543)
LSD1 inhibitor
MK-5890
CD27 agonist
21
1. Collaboration with Moderna 2. Collaboration with AstraZeneca 3. Collaboration with Eisai 4. Collaboration with Orion
5. Collaboration with Kelun Biotech 6. Includes internal pipeline programs 7. Collaboration with Daiichi Sankyo
8. Pending close of the acquisition of Harpoon Therapeutics 9. Collaborations with Dragonfly and Janux and others
2 	3
MK-1084
KRAS G12C inhibitor
MK-28705
TROP2 ADC
MK-24007
B7H3 ADC
MK-12005
Claudin 18.2 ADC
Undisclosed
preclinical ADC
targets5,6
MK-59097
CDH6 ADC	favezelimab/pembro
(MK-4280A)
anti-LAG-3
Bi-and tri-
specific T & NK
cell engagers9
MK-10227
HER3 ADC
MK-31205
Nectin-4 ADC
HPN3288
DLL3

-- 21 of 32 --

Ongoing commitment to harnessing the
power of immuno-oncology
22
Recent Approvals 	Earlier Stage Data
• 	KEYNOTE-859: FDA and EC approved KEYTRUDA in
combination with chemotherapy for first-line treatment of
adults with locally advanced unresectable or metastatic HER2
negative gastric or GEJ adenocarcinoma
• 	KEYNOTE-966: FDA and EC approved KEYTRUDA in
combination with gemcitabine and cisplatin for treatment of
patients with locally advanced unresectable or metastatic
biliary tract cancer
• 	KEYNOTE-A18: FDA approved KEYTRUDA in combination
with chemoradiotherapy for treatment of patients with FIGO
2014 Stage III through IVA cervical cancer
• 	KEYNOTE-671: Demonstrated statistically significant
improvement in OS as perioperative treatment regimen for
patients with resectable stage II, IIIA or IIIB (N2) NSCLC vs
preoperative chemotherapy
• 	KEYNOTE-564: Demonstrated statistically significant
improvement in OS as post-surgery adjuvant treatment regimen
for certain patients with RCC vs placebo
• 	KEYNOTE-123: Demonstrated statistically significant
improvement in DFS vs observation as adjuvant treatment for
high-risk patients with localized muscle invasive and locally-
advanced resectable urothelial carcinoma
• 	KEYNOTE-942: Announced positive three year follow-up data for
V940 1 in combination with KEYTRUDA for patients with resected
high-risk stage III or IV melanoma following complete resection
1. Collaboration with Moderna

-- 22 of 32 --

23
Important progress in precision and tissue targeting
1. Trial conducted in collaboration with Seagen (now Pfizer) and Astellas 2. Collaboration with Daiichi Sankyo
Precision Molecular Targeting 	Tissue Targeting
• 	LITESPARK-005: Received FDA approval for WELIREG for
treatment of adult patients with advanced RCC following a
PD-1 or PD-L1 inhibitor and a VEGF-TKI
- Additional Phase 3 trials planned for WELIREG in
combination with KEYTRUDA and/or lenvatinib in
advanced and adjuvant settings
• 	KEYNOTE-A391: Received FDA approval for KEYTRUDA in
combination with enfortumab vedotin in 1L locally advanced or
metastatic urothelial cancer
• 	HERTHENA-Lung01: Received priority review for MK-1022
(patritumab deruxtecan2) for treatment of patients with
advanced EGFR-mutated NSCLC previously treated with two or
more systemic therapies
• 	Announced pending acquisition of Harpoon Therapeutics, which
includes lead candidate HPN328, a T-cell engager targeting
(DLL3) being evaluated in SCLC and neuroendocrine tumors

-- 23 of 32 --

V116 	Sotatercept
• 	Granted priority review for prevention of invasive
pneumococcal disease and pneumococcal pneumonia in
adults (PDUFA June 17th)
• 	Additional data from STRIDE-3 as well as STRIDE-4, STRIDE-
5 and STRIDE-6 to be presented at ISPPD1 in March
• 	Potential to be first approved pneumococcal conjugate vaccine
specifically designed for adults, protecting against ~83% of
adult invasive pneumococcal disease for those 65+2
• 	Under priority review for treatment of PAH (PDUFA March 26th)
• 	Ongoing Phase 3 ZENITH and HYPERION studies, as well as
Phase 2 CADENCE study
24
Notable progress across our vaccines and cardiometabolic programs
1. International Society of Pneumonia & Pneumococcal Diseases 2. According to CDC data from 2018-2021

-- 24 of 32 --

Significant progress across our broad pipeline in 2023
25
>25
>20
Regulatory approvals
in major markets
Phase 3 studies initiated across
multiple new asset classes
Planning to initiate
an even greater
number of Phase 3
trials in 2024

-- 25 of 32 --

Q&A
Rob Davis
Chairman & Chief Executive Officer
Caroline Litchfield
Chief Financial Officer
Dr. Dean Li
President, Merck Research Laboratories
Peter Dannenbaum
Vice President, Investor Relations

-- 26 of 32 --

Appendix
27

-- 27 of 32 --

Q4 2023 GAAP financial results summary
28
Q4 2023 	Q4 2022 	Change 	Change Ex-FX
Sales 	$14.6 	$13.8 	+6% 	+7%
Operating Expenses 	$12.4 	$6.5 	+92% 	+92%
Tax Rate 	40.1% 	14.1% 	>100% 	N/A
GAAP (Loss) /
Earnings per Share ($0.48) 	$1.18 	>100% 	>100%
$ in billions, LPS/EPS amounts

-- 28 of 32 --

2023 GAAP financial results summary
29
2023 	2022 	Change 	Change Ex-FX
Sales 	$60.1 	$59.3 	+1% 	+4%
Operating Expenses 	$41.0 	$23.6 	+74% 	+75%
Tax Rate 	80.0% 	11.7% 	>100% 	N/A
GAAP
Earnings per Share $0.14 	$5.71 	-98% 	-95%
$ in billions, EPS amounts

-- 29 of 32 --

$10.4
$3.9
$7.4
$18.5
$1.3
$0
$3
$6
$9
$12
$15
$18
$21
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
Capital allocation: Trailing twelve months
~$ 18B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$10B in the U.S.
Billions
$1.76 	$1.80 	$1.84 	$1.88 	$1.92
$2.20
$2.44
$2.60
$2.76
$2.92
$1.40
$1.70
$2.00
$2.30
$2.60
$2.90
$3.20
2014 	2015 	2016 	2017 	2018 	2019 	2020 	2021 	2022 	2023
Dollars per share	
+2% 	+2% 	+2% +2% 	+2%
+11%
+15%
+7%
Over the past 12 months
Capital investments
2023 to 2027
Commitment to the dividend
30
Well positioned balance sheet
with capacity to fund
additional value-enhancing
business development
opportunities
+6%
Order of priority
+6%
1. 	Includes payments reflected in operating cash flow
2. 	Reflects R&D excluding Business Development
1
2
E

-- 30 of 32 --

Driving value for patients and shareholders by progressing our pipeline
31
Key regulatory milestones
since the last earnings call:
Key data & clinical advancements
since the last earnings call:
• 	In the U.S.:
o Approved KEYTRUDA in combination with gemcitabine and cisplatin for the treatment of
patients with locally advanced unresectable or metastatic biliary tract cancer based on KN-966.
o Approved KEYTRUDA in combination with chemotherapy for the 1L treatment of patients with
locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal
junction adenocarcinoma based on KN-859.
o Approved KEYTRUDA in combination with Padcev for the treatment of adult patients with
locally advanced or metastatic urothelial cancer based on KN-A39/EV-3021 . This approval
moves the indication to full approval from previous accelerated approval based on KN869/EV-
1031 for cisplatin-ineligible patients.
o Approved KEYTRUDA for the treatment of patients with HCC secondary to hepatitis B who
have received prior systemic therapy other than PD-1/PD-L1 containing regimen based on KN-
394. This approval moves the indication to full approval from previous accelerated approval
based on KN-224 and did not include patients with HCC secondary to hepatitis B.
o Approved KEYTRUDA in combination with chemoradiotherapy for the treatment of patients
with FIGO 2014 stage III-IVA cervical cancer based on KN-A18.
o Approved WELIREG for the treatment of adult patients with advanced renal cell carcinoma
following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI based on LITESPARK-005.
o Accepted for priority review the BLA for MK-1022 (patritumab deruxtecan 2 ) for the treatment
of patients with advanced EGFR-mutated non-small cell lung cancer previously treated with
two or more systemic therapies based on HERTHENA-Lung01.
o Accepted for priority review the BLA for V116 for the prevention of invasive pneumococcal
disease and pneumococcal pneumonia in adults based in part on STRIDE-3.
• 	In the EU:
o Approved KEYTRUDA in combination with chemotherapy for the 1L treatment of locally
advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction
adenocarcinoma in adults whose tumors express PD-L1 (CPS >/=1) based on KN-859.
o Approved KEYTRUDA in combination with gemcitabine and cisplatin for the 1L treatment of
patients with locally advanced unresectable or metastatic biliary tract cancer based on KN-966.
o Approved PREVYMIS for the prophylaxis of cytomegalovirus (CMV) disease in adult kidney
transplant recipients at high risk.
1. Trial conducted in collaboration with Seagen (now Pfizer) and Astellas 2. Collaboration with Daiichi Sankyo 3. Collaboration with Moderna 4. Collaboration with Kelun-Biotech
• 	Presented results from Phase 3 STRIDE-3 study evaluating V116, an investigational 21-
valent pneumococcal conjugate vaccine for adults, at World Vaccine Congress West
Coast.
• 	Announced Phase 3 KN-564 trial met its key secondary endpoint of overall survival for
the adjuvant treatment of patients with renal cell carcinoma at a higher risk of
recurrence following nephrectomy.
• 	Announced positive three year follow-up data from the Phase 2b randomized KN-
942/mRNA-4157-P201 study evaluating V9403 in combination with KEYTRUDA for the
treatment of patients with resected high-risk stage III/IV melanoma following
complete resection.
• 	Announced Phase 3 AMBASSADOR (A031501)/KN-123 trial statistically significant and
clinically meaningful improvement in disease-free survival vs observation for the
adjuvant treatment of high-risk patients with localized muscle-invasive urothelial
carcinoma and locally advanced resectable urothelial carcinoma.
• 	Announced Phase 3 KN-564 trial demonstrated significant improvement in overall
survival for the treatment of patients with renal cell carcinoma at intermediate-high or
high risk of recurrence following nephrectomy, or following nephrectomy and resection
of metastatic lesions.
• 	Initiated Phase 3 trials across oncology pipeline for:
o V940/mRNA-4157 3 in combination with KEYTRUDA for the adjuvant
treatment of patients with certain types of resected non-small cell lung cancer
o Bomedemstat for the treatment of certain patients with essential
thrombocythemia
o Nemtabrutinib for the treatment of certain patients with chronic lymphocytic
leukemia and small lymphocytic lymphoma
o MK-28704 for the treatment of certain patients with non-small cell lung
cancer or endometrial carcinoma
o MK-5684 for the treatment of certain patients with metastatic castration-
resistant prostate cancer

-- 31 of 32 --

Phase 2 	Phase 3 	Under regulatory review
Oncology
V181
Dengue Virus
Vaccines
Infectious diseases
MK-8189 4
Schizophrenia
Neuroscience
Gefapixant (MK-7264)5
Cough (US)
General medicine
General medicine
As of February 26, 2024
Infectious diseases
Oncology 	Oncology
MK-6024 (efinopegdutide)
NASH
MK-8527
HIV-1 prevention
MK-8591B (islatravir+MK-8507)1
HIV-1 infection
MK-8591D (islatravir+lenacapavir)2
HIV-1 infection
MK-1022 (patritumab
deruxtecan)
NSCLC (EU)
MK-1026 (nemtabrutinib)
Hematological
Malignancies
MK-1308A (quavonlimab
+pembrolizumab)
RCC
MK-2870
Endometrial
NSCLC
MK-3543
(bomedemstat)
Myeloproliferative
Disorders
KEYTRUDA (MK-3475)
CSCC (EU)
Hepatocellular (EU)
Mesothelioma
Ovarian
SCLC
MK-3475A (pembro
lizumab +hyaluronidase)
NSCLC
MK-4280A (favezelimab
+pembrolizumab)
CRC
Hematological Malignancies
MK-5684
Prostate
WELIREG (MK-6482)
RCC (EU)
LENVIMA (MK-7902)
Esophageal
Gastric
LYNPARZA (MK-7339)
NSCLC
SCLC
MK-7684A (vibostolimab
+pembrolizumab)
Melanoma
NSCLC
SCLC
V940
Melanoma
NSCLC
MK-8591A
(doravirine+islatravir)2
HIV-1 Infection
KEYTRUDA (MK-3475)
Resectable NSCLC (EU, JPN)
1L Urothelial (EU, JPN)
1L HER2- Gastric (JPN)
1L Biliary (JPN)
Endometrial Carcinoma (US)
Cervical (EU)
MK-1022 (patritumab deruxtecan)
NSCLC (US)
WELIREG (MK-6482)
Certain VHL tumors (EU)
Advanced RCC (EU)
MK-2060
Thrombosis
MK-5475
Pulmonary Arterial Hypertension
MK-7962 (sotatercept)
Pulmonary Hypertension due to Left
Heart Disease
Cardiovascular
MK-4280A
(favezelimab+pembrolizu
mab)
Bladder
cSCC
Endometrial
Esophageal
Melanoma
RCC
MK-5890 (boserolimab)
Neoplasm Malignant
KEYTRUDA (MK-3475)
Advanced Solid Tumors
Prostate
KEYTRUDA (MK-3475A)
cSCC
MK-4280
(favezelimab)
NSCLC
LYNPARZA (MK-7339)
Advanced Solid Tumors
LENVIMA (MK-7902)
HNSCC
WELIREG (MK-6482)
Endometrial
Esophageal
HCC
Prostate
Rare Cancers
MK-7684A
(vibostolimab
+pembrolizumab)
Biliary
Bladder
Breast
Cervical
CRC
Endometrial
Esophageal
Gastric
HCC
HNSCC
Ovarian
Prostate
MK-1308 (quavonlimab)
NSCLC
MK-1308A
(quavonlimab
+pembrolizumab)
CRC
MK-2140 (zilovertamab
vedotin)
Hematological Malignancies
MK-2400 (ifinatamab
deruxtecan)
SCLC
MK-2870
Neoplasm Malignant
Broad and innovative pipeline to address significant unmet medical needs
32
Vaccines
MK-1654 (clesrovimab)
Respiratory Syncytial
Virus (RSV)
1 On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials	
3 Available in the US under EUA 4 Development is co-funded by Royalty Pharma 5FDA issued CRL in December 2023
Cardiovascular
V116
Pneumococcal conjugate
vaccine, adult (EU)
MK-7240 (tulisokibart)
Ulcerative Colitis
Immunology
MK-0616
Hypercholesterolemia
MK-7962 (sotatercept)
Pulmonary Arterial Hypertension (US, EU)
Cardiovascular
LAGEVRIO (MK-4482)3
COVID-19 antiviral
Vaccines
V116
Pneumococcal conjugate vaccine, adult (US)
MK-6194
Systemic Lupus Erythematosus
Immunology

-- 32 of 32 --